✦ LIBER ✦

GRP receptors are present in non small cell lung cancer cells

✍ Scribed by Dr. T. W. Moody; F. Zia; R. Venugopal; M. Fagarasan; H. Oie; V. Hu

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 871 KB
Volume: 63
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.240630520

No coin nor oath required. For personal study only.

✦ Synopsis

Previously, GRP receptors were characterized in small cell lung cancer cells and here non-small cell lung cancer (NSCLC) cells were investigated: (1251-Tyr4) bombesin (BN) or lZ51-GRP bound with high affinity to NCLH720 (lung carcinoid) and NCI-HI 299 (large cell carcinoma) cells. Binding was specific, time dependent, and saturable. Specific (1251-Tyr4)BN binding to NCI-HI299 cells was inhibited with high affinity by GRP, BN, CRP'"27, (D-Phe6)BNG13methyl ester, moderate affinity by NMB, and low affinity by GRP1-I6. BN (10 nM) transiently elevated cytosolic calcium in a dose dependent manner. BN caused translocation of protein kinase C from the cytosol to the membrane and the translocation caused by BN was reversed by (D-Phe6)BN613methylester. BN stimulated arachidonic acid release and the increase caused by BN was reversed by (D-Phe6)BNG13methylester. Using a clonogenic assay, BN stimulated the growth of NCLH720 cells, and the number of colonies was reduced using (D-Phe6)BNG13methylester. These data suggest that GRP receptors that are present in lung carcinoid and NSCLC cells may regulate proliferation.

📜 SIMILAR VOLUMES

Somatostatin receptors are present in sm

Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: Relationship to EGF-receptors

✍ J. C. Reubi; B. Waser; M. Sheppard; V. Macaulay 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 French ⚖ 742 KB

Contemporary brachytherapy approaches in

Contemporary brachytherapy approaches in non–small-cell lung cancer

✍ Hilaris, Basil S.; Mastoras, Dina A. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Brachytherapy has the ability to deliver a higher tumor dose compared to external beam irradiation, while sparing normal tissue outside the tumor; it is the most effective means of delivering conformal radiation and can be tailored to clinical circumstances, either at open surgery or in an ambulator

HMGA2 overexpression in non-small cell l

HMGA2 overexpression in non-small cell lung cancer

✍ Britta Meyer; Siegfried Loeschke; Anke Schultze; Thomas Weigel; Martin Sandkamp; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

## Abstract Lung cancer is still the leading cause of death from cancer worldwide primarily because of the fact that most lung cancers are diagnosed at advanced stages. Overexpression of the high mobility group protein HMGA2 has been observed in a variety of malignant tumors and often correlates wi

Thorax perfusion CT in non-small cell lu

Thorax perfusion CT in non-small cell lung cancer

✍ Gulgun Yilmaz Ovali; Aysin Sakar; Cihan Göktan; Pınar Çelik; Arzu Yorgancıoğlu; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 397 KB

Objectives: We aimed to determine the perfusion differences according to the histological type, stage, volume and prognoses in the non-small cell carcinoma by thorax perfusion CT. Materials and methods: Twenty-four non-small cell carcinoma patients were included in the study. Thorax perfusion CT was

Tumor angiogenesis of non–small cell lun

Tumor angiogenesis of non–small cell lung cancer

✍ Noriharu Shijubo; Hiroshi Kojima; Manabu Nagata; Takashi Ohchi; Akihiro Suzuki; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

## Abstract Lung cancer is one of the commonest causes of cancer death in developed countries. Recent evidence suggests that angoigenesis is related to poor prognosis in many solid tumors including non–small cell lung cancer (NSCLC). Angiogenesis is regulated by a complex interaction among growth f

Adjuvant therapy of non-small cell lung

Adjuvant therapy of non-small cell lung cancer

✍ E. Carmack Holmes 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

One hundred and forty thousand patients in the United States will develop lung cancer annually. About one half of these will have disease confined to the thorax with no clinical evidence of dissemination (Figure 1). A relatively high proportion of these patients will actually have disease that can b